Sequence Bio, a biotechnology company researching the founder effect in Newfoundland and Labrador to accelerate novel drug target discovery, is pleased to announce that its Chief Scientific Officer, Dr. Michael S. Phillips, will present at Congenica’s Enabling Genomic Medicine 2020 virtual seminar.
In his presentation, Dr. Phillips will provide an overview of the migratory, geographic, and other bottleneck factors that contributed to the Newfoundland and Labrador population’s unique founder effect and resulting genetic structure. He will also describe Sequence Bio’s efforts, through its flagship genetic research study in Newfoundland and Labrador, the NL Genome Project, to develop a deeper understanding of human genetic variation in the population with an aim to identify variants that could be useful in the development of novel drug targets.
Congenica is a digital health company enabling the rapid analysis and interpretation of genomic data, empowering health professionals to provide life-changing answers to patients, helping to improve wellbeing and disease management.
Congenica’s world-leading software enables rapid genomic data analysis at scale, performing interpretation of complex genomic data 20x faster than industry averages and providing a 30% higher diagnostic yield to improve outcomes for patients and their families.
Born out of pioneering research from the Wellcome Sanger Institute and the NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.
For more information visit Congenica.com
Genomic health information is increasingly informing routine clinical care, diagnosis, and treatment for a spectrum of inherited and acquired disorders.
The accessibility of next-generation sequencing has until now outpaced the ability to understand and interpret complex data for clinical use and patient care. Overcoming this “sequencing–interpretation gap” is key to mainstreaming genomics and integrating genetic and genomic health information into routine clinical care.
With increasing improvements in clinical decision support (CDS) technologies, together with major advances in artificial intelligence (AI), the diagnostic odyssey for many patients with rare and undiagnosed disorders is now being improved significantly, demonstrating the transformational effect of genomics in health settings worldwide (Turro et al, Nature, June 2020).
At Enabling Genomic Medicine 2020: Mainstreaming Genomics – Congenica invited global experts and pioneers in the field to speak on how they are making this vision a reality.
VP, Market Development